Emergence of Psychosis in Alzheimer Disease Linked to Elevations in p-tau181
By Elana Gotkine HealthDay Reporter
MONDAY, July 1, 2024 -- For individuals with Alzheimer disease (AD), the emergence of psychosis is associated with elevations in levels of plasma tau phosphorylated at threonine 181 (p-tau181), according to a study published online June 26 in JAMA Psychiatry.
Jesus J. Gomar, Ph.D., and Jeremy Koppel, M.D., from the Feinstein Institutes for Medical Research in Manhasset, New York, examined the longitudinal dynamics of p-tau181 and neurofilament light chain protein (NfL) levels in association with the emergence of psychotic symptoms. Patients with mild cognitive impairment (MCI) and AD (with psychosis [AD+P] and without psychosis [AD−P]) and participants who were cognitively unimpaired (CU) were compared at baseline. For the longitudinal analysis, participants with MCI and AD were categorized into those with evidence of psychosis at baseline and those who showed incidence of psychosis over the course of the study. The cohort included 752 participants with AD and 424 CU participants.
The researchers found that compared with patients who had psychosis at baseline (AD+P baseline), who had a decrease in plasma p-tau181 levels over time, those who showed incidence of psychosis over the course of follow-up (AD+P incident) had an increase in plasma p-tau181 levels. In AD+P incident and AD+P baseline groups, and when only individuals with amyloid-β positivity were compared, the mean slope of p-tau181 change was significantly different. Increased levels of NfL were seen for patients who experienced psychosis at any time versus those who never experienced psychosis.
"The emergence of psychosis in AD was associated with elevations in plasma levels of p-tau181, indicating that p-tau181 may have value as a biomarker of neuropsychiatric illness in AD," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
Cognitive Impairment Delayed With Genetic Variant
THURSDAY, June 20, 2024 -- Cognitive impairment is delayed among persons who are heterozygous for the apolipoprotein E3 Christchurch variant (APOE3Ch), according to a study...
Dementia With Lewy Bodies Risk Down With α-1 Adrenergic Receptor Antagonists
WEDNESDAY, June 19, 2024 -- Men taking α-1 adrenergic receptor antagonists terazosin, doxazosin, and alfuzosin (Tz/Dz/Az) seem to have a lower risk for dementia with Lewy...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.